聚合和lipid纳米粒子:小儿科应用是什么

Philippe语言 — 2021年6月3日2.30:31+00

This review aims to provide the state of the art on polymeric and lipid nanoparticles, used or suggested to approach pediatric diseases' problems and needs, and to inspire new researches in this field.数种药目前无法配方供小儿科病人使用美国儿科配方计划建议应用新技术小儿药配方,例如纳米技术文献分析显示聚合物和脂质纳米粒子已被广泛研究治疗儿科疾病,并已在临床实践中使用核聚物纳米粒子和脂质尽管如此,这些研究几乎完全侧重于儿科癌症处理纳米医学可解决儿科疾病和医学的许多需求,但无法获取药代物学数据、药物安全性和有效性和儿科病人纳米粒子安全性限制开发以纳米粒子为基础的儿科新药单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片s/www.mdpi.com/1999-4923/13/5/670/htm2021年5月13(5)PMCID: PMC8148525.

Natural and synthetic polymer used to make pediatric nanoparticles (created with Biorender)

Natural Polymers: Albumin, Zein, Whey, Apotransferrin, Lactoferrin, Chitosan

Synthetic Polymers: Polyethylene Glycol, Poly(alkyl cyanoceyate), Poly(lactic-co-glycolic acid), Poloxamer 188, Hypromellose acetate succinate, Polyvinlypryrrodidone K30, Poly(e-caprolactone), Poly(lactic acid) Eudragit RS PO/RL PO, Poly(methyl mathacrylate), Poly(beta-amino ester)

Conclusions
Polymeric and lipid NPs have been widely studied to treat pediatric diseases, but only a few are used in therapy and only to treat pediatric cancers.高度关注使用前接收者安全易升级编程方法,当然还关注大小以获取安全载体。

因此,NP开发新儿科药时可能比较有利,不仅治疗癌症,而且还治疗慢性病,避免标签外使用和即时配方NP可按EMA和FD的要求,作为平台开发适合每个小类的适龄配方。

/derBetrag href=s/www.pharmaexsubjects.com/paedatric/congic-lipid-nanoparts/

三维打印技术开发药方的机会和挑战

Philippe语言 — Tue,16 Mars202113:30:21+00

Three-dimensional printing (3D-printing) is a technology that prints the products layer-by-layer, in which materials are deposited according to the digital model designed by computer aided design (CAD) software.技术在产品设计复杂性、产品个性化和点播制造方面有竞争优势3D技术的出现为开发新药提供创新策略和新方法本审查总结3D打印技术在制药领域的应用,重点是3D打印技术实现快速交付药、个性化交付药、复合交付药和定制交付药的优势In addition, this article illustrates the limitations and challenges of 3D printing technologies in the field of pharmaceutical formulation development.

Read the full article (open access) here: s: Cui M, Pan H, Su Y, Fang D, Qiao S, Ding P, Pan W, Opportunities and challenges of three-dimensional printing technology in pharmaceutical formulation development, ActaPharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2021.03.015.

Excipients

In the preparation process, all types of 3D printing technologies have certain requirements on the properties of excipients due to their unique printing principles.FDM技术加热和熔化步骤涉及打印过程,因此必须选择合适的药运商The carrier excipient that has been reported most frequently is PVA, but its melting temperature is relatively high, which is not suitable for thermally unstable drugs, such as 4-ASA or levetiracetam. In recent years, an increasing number of researchers have attempted to combine HME technology with 3D printing technology or low-temperature 3D printing technology, using PVP, HPMC, Kollidon, talc and triethyl citrate as excipients to prepare low-temperature printed filaments to solve the problem of drug degradation and improve drug loading.sls技术前接收者仅限于光聚合物和激光可互换材料,这些聚合物未被列入FDA公认安全列表中。

此外,安全制造预期用于药物准备DOP和SSE的重大相关长处之一是将这些技术应用到各种活性药和前接收器的可行性,如环氧树脂、奶酪、水凝胶和巧克力等即便如此,两种技术都与有机溶剂相关DOP技术选择有机溶剂打印墨水SSE技术中,可能添加有机溶剂主要是为准备软粘贴而改编剩余溶剂中某些最终三维打印平板ICH准则Q3C(R5)对溶剂有一定接受限值,因此溶剂选择有限,每种溶剂最小可接受剩余量解决这一限制,多科研究需要加强,例如开发新型三维打印机。

>sh4id=sitle0175传统准备技术经过长段实践后逐步成熟,在工业化方面独有优势。另一方面,作为一种新兴技术,三维打印可实现各种材料的精确构造并在许多方面克服传统准备技术问题开发药方打印法不仅扩大了3D打印技术的应用范围,而且还为药物调查和开发个性化药提供新方法提高药方精度和复杂性,为复合药提供基本技术支持3D打印技术仍有许多技术和监管挑战,但这些问题估计将来会解决3D打印技术将带来开发药品的新机遇和希望并加速个人化智能药的运抵。

设计应用开发即时释放拉伯卓单片

Philippe语言 — 太阳2021年2月21日 17:24:49+00

The aim of this study was to develop immediate-release oral rabeprazole sodium tablets with rapid efficacy and gastric stability for the treatment of gastroesophageal reflux disease.Rabrazole钠常用质子泵抑制器但它极不稳定并会在酸性环境中退化即时释放药方程非常有限在这次研究中,我们应用设计质量法来编译和优化IR干涂片板,内含rabapole钠内核,外加二碳酸钠层以稳定气管pH的活性药成分并调查药用量表的稳定性结果表明,开发片片约12个月稳定并高分解率,30分钟大于或等于90%并发自VivoBeagle药效学确认新开发IR平面板AUC _tTsub>max 为0.5h,比现有平板高7倍并发现IR平板立即消化腹部开发IR平板块可用作平台,以克服目前与各种质泵抑制剂相关的技术商业限制,这些抑制剂需要立即解析。

/strimentWp-at-203980'金JEa href=s/www.mdpi.com/1999-4923/13/259https://doi.org/10.3390/pharmatutics13020259

Matires

有限公司河北市研究全过程还使用下列试剂:D-manitolss/www.pharmaexcceptiers.com/exbris-suppliers-list/roquete/上海有限公司)氧化镁东岛有限公司,日本)、氢化钙药厂HendersonNVUSAhrefss/www.pharmaxlipserpses.com/product/vivastar-p/大阪有限公司,二氧化钛公司(HuntsmanCorporation,Oursburg,德国)4++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++Ludwigshafen有限公司,德国)所有其他化学物都具有分析试等级并用商业方式购买.

derBeitrag s/www.pharmaexccepties.com/binder/qbd-ir-rabepole-dry-cote-table/

SYN-004(ribaxamase)口服固态开发

Philippe语言 — 弗里2021年1月29日06:30:24+00

SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant β-lactamase enzyme designed to degrade β-lactam antibiotics administered intravenously, and thus prevent colon dysbiosis.SYN-004进片配方开发,多度实验测试。

SYN-004药物缓冲液绑定系统通过小滴预估试和电影铸模测试评价最有前景的配方用小型流化床应用运行分析分解测试和辅助分析解析氢丙基纤维素选为首选SYN-004绑定前端配方包括二维外层EUDRAGITQL30D-55聚合配方实现气管保护和肠道快速释放SYN-004-pH上升5.5附加配方改进后SYN-004负载比前代口服酶配方增加。

ThuMore on SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon

Download the article here: Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon

or continue reading here: Andrew Bristol, Steven Hubert, Felix Hofmann, Hans Baer,
Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon, International Journal of Pharmaceutics, Volume 534, Issues 1–2,
2017, Pages 25-34, ISSN 0378-5173, https://doi.org/10.1016/j.ijpharm.2017.10.001.

Excipients
Sucrose sugar spheres (Pharm-a-spheres neutral 600–710) μm, polysorbate-80, glycerin, lactose (Pharmatose® 450, polyvinyl pyrrolidone (PVP) (Kollidon® K12 and K25 hydroxypropyl cellulose), (HPC) (Klucel EF Pharm, , Triethyl Citrate (TEC) (CITROFOL® AI, low viscosity hydroxypropyl methylcellulose (HPMC) (Sheffield Biosciences, USA), Coni-Snap® hard gelatin capsules size #0 white/white, methacrylic acid – ethyl acrylate copolymer dispersion 30% (EUDRAGIT® NM 30 D), methacrylic acid – ethyl acrylate copolymer (1:1) dispersion 30% (EUDRAGIT® L 30), glycerol monostearate 40–55% (GMS) (Imwitor® 900K).

Der Beitrag Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon erschien zuerst auf Pharma Excipients.

聚合物混合应用送药

Philippe语言 — 休眠2021年1月23日15:30:39+00

Polymers are essential components of many drug delivery systems and biomedical products.尽管许多现有聚合物有实用性,但对特征和功能提高的材料需求很大。由于新启动程序批准需要广泛的安全测试,新聚合物的引进和使用非常有限。混合当前核准的聚合物提供宝贵的解决办法,解决单个聚合物的局限性问题。

Meinbody 本审查讨论聚合物混合和混合聚合物交互应用的理由网站提供商业营销产品和药送系统使用实例并讨论聚合物无定型固分解和生物分解系统实例聚合物混合分类方法基于材料处理和交互水平。

Clubation 新药分子开发挑战,如生物用量增强和对赋能前接受者的需求,将增加聚合物混合物在药用产品中的应用。

或继续读到这里: NyamweyaN.Nspringer.com/article/101186/s43094-020-00167-2FuturJ药理718(2021年)。https://doi.org/10.1186/s43094-020-00167-2

Der Beitrag Applications of polymer blends in drug delivery erschien zuerst auf Pharma Excipients.

聚合胶片内含Tenoxicam假跨模提供药系统:设计特征

Philippe语言 — 元2021年1月18日13:30:49+00

The administration of drugs via transdermal therapeutic systems has become an attractive form of therapeutic approach, considering its advantages and the high patient compliance achieved, making them a viable alternative, especially in the treatment of chronic diseases.

The purpose of our study was the development of polymer-based films containing tenoxicam (TX) and the analysis of dissolution kinetics.辅助物质代表药物形式的一个重要部分,所以在第一阶段,TX和前接收者兼容性得到验证。傅里叶变换红外光谱学和差扫描色度分析对TX和TX-HPMC < sub>E5 和TX-HPMC < sub>/sub三种聚合薄片TX(TX ₁、TX ₂和TX ₃)使用溶剂蒸发技术制作释放研究32°C++1°C使用弗朗兹扩散细胞DSC和FT-IR分析结果显示活性物质与两个矩阵编译聚合物相容性。

TX发布研究结果atpH5.5时通量值介于8.058+0.125msup2 n/span>值介于pH 5.5和0.73-0.86之间,建议扩散取决于矩阵水分和聚合松散.s安东欧亚东都兰市列台E弗拉德RA台都市门台市北南市网站s/www.mdpi.com/2227-9717/9/1/136/htm进程2021、9、136.

Der Beltrag

开发小儿小表快速预科

Philippe语言 — 介质2021年1月13日10:30:39+00

Multiple considerations are essential to address the main challenges of dose flexibility and patient adherence in pediatric drug development, particularly for oncology.微信箱直径2毫米,使用旋转片面按下定重压缩力多批量微信片物理特征一致聚合异态固体散射法(ASD)被用作提高溶性技术,增加溶性并接触ladatinib聚合前接收者分辨药释放属性的效果得到了调查。液化丙基甲基乙酸E3配方比液化丙基甲酸甲酯高百分比ASD系统内部分子间交互作用在水环境中自由药的可见溶性、物理稳定性和集中作用使用两个不同权值组(10和20kg)的少年浮游模型获取拉皮尼b药代基参数猪类研究发现剂量规范接触毒品较低,而微粒药片的剂量弹性使持续剂量水平得到控制,以达到等值等值等值等值等值二组相间等量等值感光时间剖面人类临床研究中也观察到这种线性比例化的儿科和成人群中药量springer.com/article/10.1208/s12249-0201891-x少年sporcine模型微信箱小儿药送Pharmacokinetics
Lapatinib, HPMCE3 (METHOCEL E3 Premium LV), HPMCP, Microcrystalline cellulose (Avicel® PH 200), CCS (Ac-Di-Sol®), Magnesium stearate, Colloidal silicon dioxide, methylene chloride, methanol, acetonitrile

CONCLUSION
Mini-tablets, 2 mm in diameter, were prepared using the lapatinib ASD with two different polymeric excipients (i.e., HPMCP and HPMCE3).微粒物理特性(重量、维度、抗拉强度、易碎性)在本研究中生成的所有批量相似本研究所用的制造过程适用于所显示的所有配方因子变化解析测试显示分辨值对5分至30分时段间释放剖分有影响30分钟分数后毒品释放累积量没有显著差别微型表提供动物研究的灵活性,因为给药量根据体重调整,以保持两轮相同剂量水平spani样式=text- transform:初始化;text- transform:初始化;smax

改善老年病人医学:病人特征与固口服表设计之间的考量改善摇摇经验

Philippe语言 — son,03I202115:30:33+00

Oral drug administration provided as solid oral dosage forms (SODF) remains the major route of drug therapy in primary and secondary care.有明显证据表明,老年病人口中吞吐问题(例如Disphiga)越来越多,特别是考虑到多发性、虚弱和多药化病人时更是如此。Swallowing缺陷对SODF管理有负面影响,导致加入率差和不适当的修改(例如压碎和拆分)。多年来提出了不同的策略,以便通过使用传统管理技术或吞食辅助装置增强SODF吞存经验尽管如此,新配方设计必须通过实施以病人为中心的方法加以考虑,以便有效改善老年病人对SODF的管理与适当的SODF规模缩放并发新片下载全文章:/a/p>或继续阅读斯特盖曼a hrefss/www.mdpi.com/1999-4923/13/131/32目标s药理学2021年、13年、32年/p> 摘自5章:电影编译材料设计增强SODF滚动经验 (以及出版物表7提及的专利见下)

5.1.1Polyvinyl酒精编码日本研究者开发了可膨胀平板涂层,由 >PVA 和carboxyyyl聚合物[161]组成专利应用技术也公之于众[184]另两个专利还分别描述PVA与多环酸/甘油和guar树胶/甘油Cellulose-proproymecellose片甘基coates 编码材料与gelatin[163]和agnate/sepherose其他一些配方描述gellan口香糖使用[172],并描述它与聚乙烯甘醇/高压硫酸钠的进一步组合[173]或plulan/manitol[171]此外,还报告一种配方,内含Aginiate/crice酸钠[186].

5.1.4galatin编码s sqium algate应用为增厚剂,制造涂层材料,在水摄取时积聚并形成凝胶[162]。

5.1.6wax编码 Beeswax和talc反爬行涂层获取优滑属性已在专利中披露[181].

51.7Shellac-basets 组成水溶性shellac 的材料另一种专利描述由shellac/PVP/Hycriprocolose/PEG/sucralos[187]多词性coates 双层多词性涂层材料加之cboxyecellose/PVP建议 [60]并描述丙酸共聚物配方[170].

5.1.9聚乙烯Oxide编码多环乙烷涂层建议作为润滑药用材料涂层可用涂层SODF解析法应用,后加紫外线进程[177].

5.1.10Carrageenan编码胶片改制成易片平滑面的carrageenan和tre由carangeenan/alginate/xanthan口香糖/HPMC/crospovidone组成复杂混合体已被建议为涂层材料,以提高片片吞食能力[180]包括carangeen/agar/gelatin在内的其他组合也报告[183].

a调味涂层解析法,内含通过喷洒或稀释可应用SODF的粘合物和润滑物(如聚沙分解物和多元醇)In addition, a coating gel that was obtained by polymerization and crosslinking of different polysaccharides that contributes to reduced esophageal friction was also suggested [185].

Table 7: Patents addressing new coating materials to enhance swallowability of SODF.

Der Beitrag Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience erschien zuerst auf Pharma Excipients.

各种成像技巧解析研究对Pellet推理器比较评价

Philippe语言 — 卫星2021年1月2日13:30:23+00

Most of the commercially available pharmaceutical products for oral administration route are marketed in the tablet dosage forms.压缩多片系统对制药研究产业是一个挑战,尤其是单片覆盖粒子,因为释放活性成份取决于s/www.pharmaexccidents.com/tacledored-fim-在当前研究中,聚合粒子填充不同类型前接收者(粉末、粒子、粒子)后由各种片状损耗性(微镜)和片片非损耗性(微焦X射线)调查micCT成像方法从体外药物释放剖面模型独立评价中获取的信息通过图像分析结果得到确认,而无论涂层表粒片片片片片片片片片片片片片片片片片片片片片片片片片片片片片分析使用X光片片或立体显像片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片片研究结果显示,新奇易用快速非破坏性MFX法是本用微镜分析法的好替代方法,即粒子定性压缩成片片片片.

Dowload全文章: /ahref=s/www.ffarmaexbidents.com/wp-content/uploads/2021/01/Compatiation-Evale-of-Cushiong-Agents逐行编译-Techniques-Disolation-Studies.pdf>et al.springer.com/article/10.1208/s12249-020902-xAAPS药理技术2214(2021年)。https://doi.org/10.1208/s12249-020-01902-x

Materials: Ph.欧尔八级氯化钾、微信素3102目标ss/www.pharmaexcceptiers.com/product/ax-105Benecel+E3药理)

/der Betrag

含高视觉聚合物和中聚Silica增强分解性能

Philippe语言 — 太阳2020年12月13日

srcs/www.pharmaexsubjects.com/wp-content/uploads/2020/12/Ternary-Adivous-Solid-DisTernaryASD粒子由热熔化生成,由iraconazole(ITZ) 50%、hyprolesse(HPMC) 20%和misorous Silica(XDP) 30%组成,HPPC内无变ITZ高效吸收含高敏度HPPC(AF4M)的永久ASD粒子在中性pH解析介质中产生药超饱和能力显著提高,晶体ITZ溶性低于1mg/ml最终平板配方含ASD粒子80% w/w(40% w/wITZ),体积可接受,并展示出足够的平板硬度和分解性单片解析显示超饱和维护能力类似于单片粒子中性条件下,自定义asd平板显示ITZ即时释放量高于二进制asd平板,这种现象可以用ITZ/AF4M粒子大小差异来解释。高分辨率扫描电子显微镜显示,长效配方ITZ和AF4M在HME编译入/转入XDP孔片过程期间很容易生成纳米级粒子(<1m),这有助于从sternad平板上立即释放ITZ中中立pH条件由HME制作的含有高敏感度HPMC和多孔硅片的永久ASD使设计高ASD小片片和理想分解生物相关媒体成为可能,我们期望该技术可应用到HMEACD连续制造中。

见此文章

Jermain Stephen A汤普森、Hirosuke Furuta、Mamoru福田和Robert OWilliams IIIBR/Pharmaceutics 2020, XXXX, XXX, XXX-XXX,
Publication Date:December 8, 2020
https://doi.org/10.1021/acs.molpharmaceut.0c00811

KEYWORDS: amorphous solid dispersion, hot melt extrusion, mesoporous silica (Syloid XDP 3050), HPMC (Affinisol HPMC HME 15LV, Affinisol HPMC HME 100LV, Affinisol HPMC HME 4M), Itraconazole (ITZ), Lactose monohydrate (InhaLac 230), Croscarmellose sodium (KICCOLATE)

Der Beitrag Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance erschien zuerst auf Pharma Excipients.

评估X射线微量图象的不同预处理方法

Philippe语言 — wed, 09 2020年12月13:30:26+00

Adequate images of real tablets provide the possibility to validate in silico software tools like F-CAD.这项工作的目的是评价X射线微量摄像头12批不同片段的不同预处理方法的影响图像用开源软件imageJ处理应用不同的漂白和闪电校正.

大规模使用固态分布技术聚合载体概述

Philippe语言 — 周五 2020年11月23日 10:30+00

Solid dispersion is the preferred technology to prepare efficacious forms of BCS class-II/IV APIs.准备固化散射,有各种聚合载体,配方科学家可调用这些载体,这些载体有有趣的物理化学特征和热化特征。自固散技术于1960年代初出现以来,已有5000多篇科学论文发布于主题领域聚合载量属性多解 PVP、Copovidone、PEG、HPCC、HPMCAS和/span+/stropenspan样式='Text-Technology.pdf'et al.springer.com/article/10.1208/s12249-020849-z#citeas目标AAPS药理21309(2020年)。https://doi.org/10.1208/s12249-020-01849-z

This article gives a great overview and covers the following topics:

CLASSIFICATION OF POLYMERIC CARRIERS
SELECTION CRITERIA FOR POLYMERIC CARRIERS
VINYL PYRROLIDONE DERIVATIVES
POLY VINYL PYRROLIDONE (PVP)
COPOVIDONE
POLY ETHYLENE GLYCOL (PEG)
CELLULOSE DERIVATIVES
HYDROXY PROPYL METHYL CELLULOSE (HPMC)
HYDROXY PROPYL METHYL CELLULOSE ACETATE SUCCINATE (HPMCAS)
SOLUPLUS®
MANUFACTURING ISSUES OF POLYMERS IN SOLID DISPERSION TECHNOLOGY

Some interesting "outtakes" from this publication

Table I Various Types of Solid Dispersions and Their Relative Potential for Stability and Solubility Improvement

Table II Physicochemical Properties of Polymers Commonly Used in the Preparation of Solid Dispersions

Polymer	Type	Physical form	Molecular weight (g/Mol)	Water solubility	Hygroscopicity	Glass transition/Melting temperature (°C)	Degradation temperature (°C)	Solubility parameter (Mpa1/2)
Poly-Vinyl-Pyrrolidone (PVP)	PVP K-12	Amorphous	5000	Water soluble	High	120a	196	21.74
Poly-Vinyl-Pyrrolidone (PVP)	PVP K-15	Amorphous	9700	Water soluble	High	130a	215	21.63
Poly-Vinyl-Pyrrolidone (PVP)	PVP K-30	Amorphous	66,800	Water soluble	High	163a	171	21.69
Poly-Vinyl-Pyrrolidone (PVP)	PVP K-60	Amorphous	396,000	Water soluble	High	170a	NA	21.7
Poly-Vinyl-Pyrrolidone (PVP)	PVP K-90	Amorphous	1,570,000	Water soluble	High	174a	194	21.73
Poly-Vinyl-Pyrrolidone (PVP)	PVP K-120	Amorphous	3,470,000	Water soluble	High	174a	194	21.7
Copovidone	Copovidone	Amorphous	45,000–70,000	Amphiphilic	Moderate	100–105	230	21.2
Poly ethylene glycol (PEG)	PEG 400	Crystalline	400	Intermediate	High	NA	NA	18.9
Poly ethylene glycol (PEG)	PEG 600	Crystalline	600	Intermediate	High	NA	160	23.7
Poly ethylene glycol (PEG)	PEG 800	Crystalline	800	Intermediate	High	NA	160	23.7
Poly ethylene glycol (PEG)	PEG 1000	Crystalline	1000	Intermediate	Moderate	37–40	160	23.7
Poly ethylene glycol (PEG)	PEG 1500	Crystalline	1500	Intermediate	Moderate	44–48	160	23.7
Poly ethylene glycol (PEG)	PEG 2000	Crystalline	2000	Intermediate	Moderate	45–50	160	17.6
Poly ethylene glycol (PEG)	PEG 3000	Crystalline	3000	Intermediate	Moderate	48–54	NA	NA
Poly ethylene glycol (PEG)	PEG 4000	Crystalline	4000	Intermediate	Moderate	50–58	NA	NA
Poly ethylene glycol (PEG)	PEG 6000	Crystalline	6000	Intermediate	Moderate	55–63	NA	NA
Poly ethylene glycol (PEG)	PEG 8000	Crystalline	8000	Intermediate	Moderate	60–63	NA	19.8
Poly ethylene glycol (PEG)	PEG 10000	Crystalline	10,000	Intermediate	Moderate	62–65	NA	16.6
Poly ethylene glycol (PEG)	PEG 20000	Crystalline	20,000	Intermediate	Moderate	60–63	NA	NA
Hydroxypropyl methylcellulose (HPMC)	HPMC-E	Amorphous	85,000–150,000	Water soluble	High	141c	NA	29.95b
Hydroxypropyl methylcellulose (HPMC)	HPMC-F	Amorphous	85,000–150,000	Water soluble	High	160c	240	29.05b
Hydroxypropyl methylcellulose (HPMC)	HPMC-K	Amorphous	85,000–150,000	Water soluble	High	172c	260	30.57b
Hydroxypropyl methylcellulose acetate succinate (HPMCAS)	HPMCAS L	Amorphous	50,000	Water soluble above pH 5.0	High	119	204	29.1
Hydroxypropyl methylcellulose acetate succinate (HPMCAS)	HPMCAS M	Amorphous	50,000	Water soluble above pH 5.0	High	120	190	29.1
Hydroxypropyl methylcellulose acetate succinate (HPMCAS)	HPMCAS H	Amorphous	50,000	Water soluble above pH 5.0	High	122	NA	29.1
Soluplus®	Soluplus®	Amorphous	118,000	Amphiphilic	Moderate	70	250	19.4

Der Beitrag Overview of Extensively Employed Polymeric Carriers in Solid Dispersion Technology erschien zuerst auf Pharma Excipients.

固分解潜力提高溶性、生物可用性以及不良水溶性药的治疗效果:更新配方技术、当前市场化假想和专利

Philippe语言 — 太阳2020年11月22日16:43:25+00

In the last few decades, solid dispersion (SD) technology had been studied as an approach to produce an amorphous carrier to enhance the solubility, dissolution rate, and bioavailability of poorly water-soluble drugs.使用合适的载波方法准备自定义在自定义生物行为中发挥重要作用sds编译使用各种药用可接受聚合物使用各种新技术近些年来,人们多加注意使用新运量方法探索新型自定义提高治疗效果和生物可用性使用新运算器和方法将非常有利于配方科学家开发某些基于SDs的配方供商业使用和临床应用在当前审查中,归纳分析新方法文献,提高溶解率、溶性、治疗效果和低水溶性药物生物可用性SDs当前状态、专利状态和未来前景也得到了讨论。

squative-effective-effice-pote-drues-newer-formations.pdf>固态分布增强水溶性药新配方生物可用性和治疗效率Altamii NabilKAlruwaili , Fahad Alotaibi , Abdullah Alanazi & Faiyaz Shakeel (2020) Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents, Drug Delivery, 27:1, 1625-1643, DOI: 10.1080/10717544.2020.1846638

Some further insights of this article

Drug	Carrier	Method
Nifedipine, efavirenz	Hydroxypropyl methylcellulose acetate succinate	Hot melt extrusion
Mefenamic acid	EudragitVR EPO	Hot melt extrusion
Mefenamic acid	Kollidon® 12 PF and 17 PF	Hot melt extrusion
Carbamazepine	Soluplus®	Hot melt extrusion
Piperine	Eudragit® EPO, Kollidon® VA 64, Soluplus®	Hot melt extrusion
Lansoprazole	Kollidon® 12 PF, Lutrol® F 68, MgO	Hot melt extrusion
Aripiprazole	Kollidon® 12 PF (PVP) and succinic acid	Hot-melt extrusion
Hydrocortisone	Polyethylene glycol 4000 (PEG 4000), Kolliphor® P 407	Spray drying
Apigenin	Pluronic-F127	Microwave irradiation
Mefenamic acid and flufenamic acid	Pluronic F127® (PL), Eudragit EPO® (EPO), polyethylene glycol 4000 (PEG 4000), Gelucire 50/13 (GLU)	Microwave irradiation
Nifedipine, sulfamethoxazole	Soluplus®, PEG 6000	Spray drying, lyophilization
Efavirenz	href="//www.novoestroim.com/www2/product/soluplus/">Soluplus®	Spray-drying
Apigenin	Pluronic F 127	Spray drying
Sirolimus	Eudragit® E HPMC	Spray drying

Der Beitrag Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents erschien zuerst auf Pharma Excipients.

聚合型、ASD加载和聚合药比对ASD片分解和释放

Philippe语言 — wed,2020年11月18日06:13:02+00

Amorphous solid dispersion (ASD) has become an attractive strategy to enhance solubility and bioavailability of poorly water-soluble drugs.方便口语管理,ASD常入片片分解和从asd片片解毒对实现非定型药固有溶性优势至关重要。这项工作系统研究聚合物类型Assd加载片片和聚合药比Assd对Assd片分解和释放药的影响评估了2个水益聚合物PVA和HPCC和1个相对疏水聚合物HPMCAS解析测试进行,分解时间记录解析测试随着ASD加载增加,所有三种聚合ASD片段的片段分解时间增加,对流益聚合asd片段效果更显眼聚合药比提高后,药片分解时间增加后,基于水益聚合片片片,但HPMCAS单片仍短且基本不变。高ACD加载或高聚合药比时,HPMCASa片片比PVA-或HPCa这些结果归结为聚合物水益求异和聚合物水求异这项工作对理解ASD片片片分解和药物释放很有价值,从下游片面配方角度为ACSD组成选择提供洞察力Continue on Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release

Keywords: Amorphous formulation, ASD tablet, disintegration, dissolution, PVPVA (Kollidon VA64), HPMC (Methocel E5 Premium LV), HPMCAS-MF, dichloromethane, methanol, Avicel PH102 (Microcrystalline Cellulose, Lactose Fast Flo 316 croscarmellose sodium, magnesium stearate

Innovative Technologies for amorphous solid dispersions

Der Beitrag Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release erschien zuerst auf Pharma Excipients.

CelluloseEthers-Pharma前接收器